Omegaven (Glycerol, Highly Refined Fish Oil, Purified Egg Phospholipids)

Omegaven supplies highly refined fish oil, glycerol and purified egg phospholipids directly into the bloodstream. The omega‑3 fatty acids (EPA and DHA) become part of cell membranes, modulating inflammatory pathways, supporting membrane integrity, and delivering essential fatty acids and energy needed for patients who cannot receive nutrition enterally.

The dose of Omegaven is individualized by the prescribing clinician based on the patient’s caloric needs, lipid requirements, and clinical condition. Healthcare professionals calculate the appropriate volume and infusion rate according to established parenteral nutrition protocols and laboratory monitoring.

Safety data for Omegaven in pregnancy and lactation are limited, and the product’s pregnancy category is not established. Use during pregnancy or while breastfeeding should only occur if the potential benefits justify any potential risk, and it must be decided by the treating physician.

To order Omegaven, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and any necessary import documentation.

Omegaven is distinguished by its high content of omega‑3 fatty acids from fish oil, which offers anti‑inflammatory benefits and a different fatty‑acid profile compared with traditional soybean‑based emulsions. This can result in lower triglyceride levels and reduced risk of liver dysfunction, making it a preferred option for patients at risk of inflammation‑related complications.

Omegaven must be stored at 2‑8 °C in a refrigerator. Keep the container in its original packaging, protect it from light, and avoid freezing or vigorous shaking. Before use, gently invert the bag to ensure uniform suspension of the emulsion.

Omegaven is administered intravenously as a sterile emulsion, typically infused through a central venous catheter as part of a total parenteral nutrition regimen. The infusion rate and total daily volume are determined by the prescribing clinician and are adjusted according to the patient’s metabolic response and laboratory results.

Serious risks include fat overload syndrome, severe hypertriglyceridaemia that can lead to pancreatitis, anaphylactic reactions, coagulopathy, and infection related to the lipid medium. Clinicians should monitor triglyceride levels, liver function, coagulation parameters and observe patients for any signs of allergic response during infusion.

Omegaven should be avoided in patients with known hypersensitivity to fish oil, egg phospholipids, or any component of the formulation. It is also contraindicated in individuals with severe hyperlipidaemia where the risk of fat overload outweighs benefits, and in patients with uncontrolled sepsis or active infection where lipid infusion could exacerbate the condition.